Membrane Topology of the C. Elegans SEL-12 Presenilin
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Hemolysin from Escherichia Coli Uses Endogenous Amplification Through P2X Receptor Activation to Induce Hemolysis
␣-Hemolysin from Escherichia coli uses endogenous amplification through P2X receptor activation to induce hemolysis Marianne Skalsa, Niklas R. Jorgensenb, Jens Leipzigera, and Helle A. Praetoriusa,1 aDepartment of Physiology and Biophysics, Water and Salt Research Center, Aarhus University, Ole Worms Alle 1160, 8000 Aarhus C, Denmark; and bDepartment for Clinical Biochemistry, Roskilde Hospital, Koegevej 3-7, 4000 Roskilde, Denmark Edited by Sucharit Bhakdi, University of Mainz, Mainz, Germany, and accepted by the Editorial Board January 6, 2009 (received for review July 22, 2008) Escherichia coli is the dominant facultative bacterium in the normal and are referred to as P2X1–7. All P2X receptors are permeable to intestinal flora. E. coli is, however, also responsible for the majority small monovalent cations and some have significant calcium per- of serious extraintestinal infections. There are distinct serotypical meability (11). Here we show that human, murine, and equine differences between facultative and invasive E. coli strains. Inva- erythrocytes use a combination of P2X1 and P2X7 receptor acti- sive strains frequently produce virulence factors such as ␣-hemolysin vation for full HlyA-induced hemolysis to occur. This is particularly (HlyA), which causes hemolysis by forming pores in the erythrocyte interesting, as prolonged stimulation of P2X7 receptors are known membrane. The present study reveals that this pore formation to increase the plasma membrane permeability to an extent that triggers purinergic receptor activation to mediate the full hemo- eventually leads to lysis of certain cells (12). In macrophages it has lytic action. Non-selective ATP-receptor (P2) antagonists (PPADS, been shown that pannexin1, a recently discovered pore-forming suramin) and ATP scavengers (apyrase, hexokinase) concentration protein, is required for this increment in permeability (12, 13). -
Disposal of Toxin Heptamers by Extracellular Vesicle Formation and Lysosomal Degradation
toxins Article Major Determinants of Airway Epithelial Cell Sensitivity to S. aureus Alpha-Toxin: Disposal of Toxin Heptamers by Extracellular Vesicle Formation and Lysosomal Degradation Nils Möller 1,* , Sabine Ziesemer 1, Christian Hentschker 2, Uwe Völker 2 and Jan-Peter Hildebrandt 1 1 Animal Physiology and Biochemistry, University of Greifswald, Felix Hausdorff-Strasse 1, D-17489 Greifswald, Germany; [email protected] (S.Z.); [email protected] (J.-P.H.) 2 Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Felix Hausdorff-Strasse 8, D-17475 Greifswald, Germany; [email protected] (C.H.); [email protected] (U.V.) * Correspondence: [email protected] Abstract: Alpha-toxin is a major virulence factor of Staphylococcus aureus. Monomer binding to host cell membranes results in the formation of heptameric transmembrane pores. Among human model airway epithelial cell lines, A549 cells were most sensitive toward the toxin followed by 16HBE14o- and S9 cells. In this study we investigated the processes of internalization of pore-containing plasma membrane areas as well as potential pathways for heptamer degradation (lysosomal, proteasomal) or disposal (formation of exosomes/micro-vesicles). The abundance of toxin heptamers upon applying an alpha-toxin pulse to the cells declined both in extracts of whole cells and of cellular membranes of Citation: Möller, N.; Ziesemer, S.; S9 cells, but not in those of 16HBE14o- or A549 cells. Comparisons of heptamer degradation rates un- Hentschker, C.; Völker, U.; der inhibition of lysosomal or proteasomal degradation revealed that an important route of heptamer Hildebrandt, J.-P. -
343747488.Pdf
Washington University School of Medicine Digital Commons@Becker Open Access Publications 6-1-2020 Systematic validation of variants of unknown significance in APP, PSEN1 and PSEN2 Simon Hsu Anna A Pimenova Kimberly Hayes Juan A Villa Matthew J Rosene See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Authors Simon Hsu, Anna A Pimenova, Kimberly Hayes, Juan A Villa, Matthew J Rosene, Madhavi Jere, Alison M Goate, and Celeste M Karch Neurobiology of Disease 139 (2020) 104817 Contents lists available at ScienceDirect Neurobiology of Disease journal homepage: www.elsevier.com/locate/ynbdi Systematic validation of variants of unknown significance in APP, PSEN1 T and PSEN2 Simon Hsua, Anna A. Pimenovab, Kimberly Hayesa, Juan A. Villaa, Matthew J. Rosenea, ⁎ Madhavi Jerea, Alison M. Goateb, Celeste M. Karcha, a Department of Psychiatry, Washington University School of Medicine, 425 S Euclid Avenue, St Louis, MO 63110, USA b Department of Neuroscience, Mount Sinai School of Medicine, New York, NY, USA ARTICLE INFO ABSTRACT Keywords: Alzheimer's disease (AD) is a neurodegenerative disease that is clinically characterized by progressive cognitive APP decline. More than 200 pathogenic mutations have been identified in amyloid-β precursor protein (APP), presenilin PSEN1 1 (PSEN1) and presenilin 2 (PSEN2). Additionally, common and rare variants occur within APP, PSEN1, and PSEN2 PSEN2 that may be risk factors, protective factors, or benign, non-pathogenic polymorphisms. Yet, to date, no Alzheimer's disease single study has carefully examined the effect of all of the variants of unknown significance reported in APP, Cell-based assays PSEN1 and PSEN2 on Aβ isoform levels in vitro. -
Genetic Testing for Familial Alzheimer's Disease
Corporate Medical Policy Genetic Testing for Familial Alzheimer’s Disease AHS – M2038 File Name: genetic_testing_for_familial_alzheimers_disease Origination: 1/2019 Last CAP Review: 10/2020 Next CAP Review: 10/2021 Last Review: 10/2020 Description of Procedure or Service Alzheimer disease (AD) is a neurodegenerative disease defined by a gradual decline in memory, cognitive functions, gross atrophy of the brain, and an accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles (Karch, Cruchaga, & Goate, 2014). Familial Alzheimer disease (FAD) is a rare, inherited form of AD. FAD has a much earlier onset than other forms of Alzheimer disease with symptoms developing in individuals in their thirties or forties. Related Policies General Genetic Testing, Germline Disorders AHS – M2145 General Genetic Testing, Somatic Disorders AHS – M2146 ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician. Policy BCBSNC will provide coverage for genetic testing for familial Alzheimer disease when it is determined the medical criteria or reimbursement guidelines below are met. Benefits Application This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy. -
Transport Proteins Promoting Escherichia Coli Pathogenesis
Microbial Pathogenesis 71-72 (2014) 41e55 Contents lists available at ScienceDirect Microbial Pathogenesis journal homepage: www.elsevier.com/locate/micpath Transport proteins promoting Escherichia coli pathogenesis Fengyi Tang 1, Milton H. Saier Jr. * Department of Molecular Biology, Division of Biological Sciences, University of California at San Diego, La Jolla, CA 92093-0116, USA article info abstract Article history: Escherichia coli is a genetically diverse species infecting hundreds of millions of people worldwide Received 26 November 2013 annually. We examined seven well-characterized E. coli pathogens causing urinary tract infections, Received in revised form gastroenteritis, pyelonephritis and haemorrhagic colitis. Their transport proteins were identified and 19 March 2014 compared with each other and a non-pathogenic E. coli K12 strain to identify transport proteins related Accepted 20 March 2014 to pathogenesis. Each pathogen possesses a unique set of protein secretion systems for export to the cell Available online 18 April 2014 surface or for injecting effector proteins into host cells. Pathogens have increased numbers of iron siderophore receptors and ABC iron uptake transporters, but the numbers and types of low-affinity Keywords: Escherichia coli secondary iron carriers were uniform in all strains. The presence of outer membrane iron complex re- fi Pathogenesis ceptors and high-af nity ABC iron uptake systems correlated, suggesting co-evolution. Each pathovar Transporters encodes a different set of pore-forming toxins and virulence-related outer membrane proteins lacking in Toxins K12. Intracellular pathogens proved to have a characteristically distinctive set of nutrient uptake porters, Iron acquisition different from those of extracellular pathogens. The results presented in this report provide information Intra vs. -
N-Glycan Trimming in the ER and Calnexin/Calreticulin Cycle
Neurotransmitter receptorsGABA and A postsynapticreceptor activation signal transmission Ligand-gated ion channel transport GABAGABA Areceptor receptor alpha-5 alpha-1/beta-1/gamma-2 subunit GABA A receptor alpha-2/beta-2/gamma-2GABA receptor alpha-4 subunit GABAGABA receptor A receptor beta-3 subunitalpha-6/beta-2/gamma-2 GABA-AGABA receptor; A receptor alpha-1/beta-2/gamma-2GABA receptoralpha-3/beta-2/gamma-2 alpha-3 subunit GABA-A GABAreceptor; receptor benzodiazepine alpha-6 subunit site GABA-AGABA-A receptor; receptor; GABA-A anion site channel (alpha1/beta2 interface) GABA-A receptor;GABA alpha-6/beta-3/gamma-2 receptor beta-2 subunit GABAGABA receptorGABA-A receptor alpha-2receptor; alpha-1 subunit agonist subunit GABA site Serotonin 3a (5-HT3a) receptor GABA receptorGABA-C rho-1 subunitreceptor GlycineSerotonin receptor subunit3 (5-HT3) alpha-1 receptor GABA receptor rho-2 subunit GlycineGlycine receptor receptor subunit subunit alpha-2 alpha-3 Ca2+ activated K+ channels Metabolism of ingested SeMet, Sec, MeSec into H2Se SmallIntermediateSmall conductance conductance conductance calcium-activated calcium-activated calcium-activated potassium potassium potassiumchannel channel protein channel protein 2 protein 1 4 Small conductance calcium-activatedCalcium-activated potassium potassium channel alpha/beta channel 1 protein 3 Calcium-activated potassiumHistamine channel subunit alpha-1 N-methyltransferase Neuraminidase Pyrimidine biosynthesis Nicotinamide N-methyltransferase Adenosylhomocysteinase PolymerasePolymeraseHistidine basic -
Cerebrospinal Fluid Biomarkers for Differentiating Between Alzheimer‟S Disease and Vascular Dementia
Cerebrospinal fluid biomarkers for differentiating between Alzheimer‟s disease and Vascular dementia Maria Bjerke Institute of Neuroscience and Physiology Department of Psychiatry and Neurochemistry The Sahlgrenska Academy Gothenburg University 2011 ISBN 978-91-628-8312-6 © Maria Bjerke Institute of Neuroscience and Physiology Gothenburg University Sweden Printed at Intellecta Infolog Gothenburg Sweden, 2011 To my family ABSTRACT Patients suffering from mild cognitive impairment (MCI) run a higher risk of developing dementia, with Alzheimer‟s disease (AD) being the most common form. Vascular dementia (VaD) is proposed to be the second most common dementia entity, and it includes the clinically relatively homogenous subgroup of subcortical vascular dementia (SVD). Varying degrees of concomitant vascular lesions represent a link between AD and VaD, comprising a state of mixed dementia (MD). Biochemical markers provide important information which may contribute to differentiating between dementias of different etiologies, and in combination with the clinical assessment may improve diagnostic accuracy. The overall aim of this thesis is to provide for better separation between patients suffering from SVD and AD with the aid of biochemical markers. The cerebrospinal fluid (CSF) biomarkers T-tau, P-tau181, and Aβ1-42, have proven useful in distinguishing MCI patients who ultimately develop AD (MCI-AD) at follow-up from those who remain stable. However, less is known about the biomarker pattern in MCI patients who develop SVD (MCI-SVD). An elevated baseline level of NF-L was found in MCI-SVD patients compared with stable MCI patients, while MCI-AD had decreased levels of Aβ1-42 and increased levels of T- tau and P-tau181 compared with MCI-SVD patients and stable MCI patients. -
Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes
Tohoku J. Exp. Med., 2011,Differential 223, 161-176 Gene Expression in OPCs, Oligodendrocytes and Type II Astrocytes 161 Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes Jian-Guo Hu,1,2,* Yan-Xia Wang,3,* Jian-Sheng Zhou,2 Chang-Jie Chen,4 Feng-Chao Wang,1 Xing-Wu Li1 and He-Zuo Lü1,2 1Department of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Bengbu, P.R. China 2Anhui Key Laboratory of Tissue Transplantation, Bengbu Medical College, Bengbu, P.R. China 3Department of Neurobiology, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China 4Department of Laboratory Medicine, Bengbu Medical College, Bengbu, P.R. China Oligodendrocyte precursor cells (OPCs) are bipotential progenitor cells that can differentiate into myelin-forming oligodendrocytes or functionally undetermined type II astrocytes. Transplantation of OPCs is an attractive therapy for demyelinating diseases. However, due to their bipotential differentiation potential, the majority of OPCs differentiate into astrocytes at transplanted sites. It is therefore important to understand the molecular mechanisms that regulate the transition from OPCs to oligodendrocytes or astrocytes. In this study, we isolated OPCs from the spinal cords of rat embryos (16 days old) and induced them to differentiate into oligodendrocytes or type II astrocytes in the absence or presence of 10% fetal bovine serum, respectively. RNAs were extracted from each cell population and hybridized to GeneChip with 28,700 rat genes. Using the criterion of fold change > 4 in the expression level, we identified 83 genes that were up-regulated and 89 genes that were down-regulated in oligodendrocytes, and 92 genes that were up-regulated and 86 that were down-regulated in type II astrocytes compared with OPCs. -
Tailored Liposomal Nanotraps for the Treatment of Streptococcal Infections
Besançon et al. J Nanobiotechnol (2021) 19:46 https://doi.org/10.1186/s12951-021-00775-x Journal of Nanobiotechnology RESEARCH Open Access Tailored liposomal nanotraps for the treatment of Streptococcal infections Hervé Besançon1 , Viktoriia Babiychuk1, Yu Larpin1, René Köfel1, Dominik Schittny1, Lara Brockhus1, Lucy J. Hathaway2, Parham Sendi2, Annette Draeger1^ and Eduard Babiychuk1* Abstract Background: Streptococcal infections are associated with life-threatening pneumonia and sepsis. The rise in anti- biotic resistance calls for novel approaches to treat bacterial diseases. Anti-virulence strategies promote a natural way of pathogen clearance by eliminating the advantage provided to bacteria by their virulence factors. In contrast to antibiotics, anti-virulence agents are less likely to exert selective evolutionary pressure, which is a prerequisite for the development of drug resistance. As part of their virulence mechanism, many bacterial pathogens secrete cytol- ytic exotoxins (hemolysins) that destroy the host cell by destabilizing their plasma membrane. Liposomal nanotraps, mimicking plasmalemmal structures of host cells that are specifcally targeted by bacterial toxins are being developed in order to neutralize-by competitive sequestration-numerous exotoxins. Results: In this study, the liposomal nanotrap technology is further developed to simultaneously neutralize the whole palette of cytolysins produced by Streptococcus pneumoniae, Streptococcus pyogenes and Streptococcus dys- galactiae subspecies equisimilis-pathogens that -
Genomic Plasticity of the Causative Agent of Melioidosis, Burkholderia Pseudomallei
Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei Matthew T. G. Holdena, Richard W. Titballb,c, Sharon J. Peacockd,e, Ana M. Cerden˜ o-Ta´ rragaa, Timothy Atkinsb, Lisa C. Crossmana, Tyrone Pittf, Carol Churchera, Karen Mungalla, Stephen D. Bentleya, Mohammed Sebaihiaa, Nicholas R. Thomsona, Nathalie Basona, Ifor R. Beachamg, Karen Brooksa, Katherine A. Brownh, Nat F. Browng, Greg L. Challisi, Inna Cherevacha, Tracy Chillingwortha, Ann Cronina, Ben Crossetth, Paul Davisa, David DeShazerj, Theresa Feltwella, Audrey Frasera, Zahra Hancea, Heidi Hausera, Simon Holroyda, Kay Jagelsa, Karen E. Keithh, Mark Maddisona, Sharon Moulea, Claire Pricea, Michael A. Quaila, Ester Rabbinowitscha, Kim Rutherforda, Mandy Sandersa, Mark Simmondsa, Sirirurg Songsivilaik, Kim Stevensa, Sarinna Tumapae, Monkgol Vesaratchaveste, Sally Whiteheada, Corin Yeatsa, Bart G. Barrella, Petra C. F. Oystonb, and Julian Parkhilla,l aWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, United Kingdom; bDefence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, United Kingdom; cDepartment of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; dNuffield Department of Clinical Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, United Kingdom; eFaculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand; fLaboratory of Hospital Infection, Division of Nosocomial Infection Prevention and Control, Central Public Health Laboratory, London NW9 5HT, United Kingdom; gSchool of Health Science, Griffith University, Gold Coast, Queensland 9726, Australia; hDepartment of Biological Sciences, Centre for Molecular Microbiology and Infection, Flowers Building, Imperial College, London SW7 2AZ, United Kingdom; iDepartment of Chemistry, University of Warwick, Coventry CV4 7AL, United Kingdom; jU.S. -
1 Presenilin-Based Genetic Screens in Drosophila Melanogaster Identify
Genetics: Published Articles Ahead of Print, published on January 16, 2006 as 10.1534/genetics.104.035170 Presenilin-based genetic screens in Drosophila melanogaster identify novel Notch pathway modifiers Matt B. Mahoney*1, Annette L. Parks*2, David A. Ruddy*3, Stanley Y. K. Tiong*, Hanife Esengil4, Alexander C. Phan5, Panos Philandrinos6, Christopher G. Winter7, Kari Huppert8, William W. Fisher9, Lynn L’Archeveque10, Felipa A. Mapa11, Wendy Woo, Michael C. Ellis12, Daniel Curtis11 Exelixis, Inc., South San Francisco, California, 94083 Present addresses: 1Department of Discovery, EnVivo Pharmaceuticals, Watertown, Massachusetts, 02472 2Biology Department, Boston College, Chestnut Hill, Massachusetts, 02467 3Oncology Targets and Biomarkers, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts, 02139 4Department of Molecular Pharmacology, Stanford University, Stanford, California, 94305 5Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205 6ITHAKA Academic Cultural Program in Greece, San Francisco, California, 94102 7Merck Research Laboratories, Boston, Massachusetts, 02115 8Donald Danforth Plant Science Center, St. Louis, Missouri, 63132 1 9Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, 94720 10Biocompare, Inc., South San Francisco, California, 94080 11Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts, 02139 12Renovis, Inc., South San Francisco, California, 94080 -
Structural and Biochemical Studies of the Human Two Pore Domain Potassium Channel K2P1
STRUCTURAL AND BIOCHEMICAL STUDIES OF THE HUMAN TWO PORE DOMAIN POTASSIUM CHANNEL K2Pl by Alexandria Nuesa Miller A Dissertation Presented to the Faculty ofthe Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy New York, NY April, 2013 ~y;} c;, ZD/3 s~ Date Dissertation Mentor Copyright by Alexandria N. Miller 2013 ABSTRACT Potassium (K+) channels are the largest family of ion channels in eukaryotes with over 70 genes in humans. They have diverse functional roles including controlling the firing duration and frequency of actions potentials in neurons and regulating water retention in the kidneys. K+ channels are highly-selective for K+ over other monovalent cations, can conduct K+ at rates approaching 108 ions per second and, like other ion channels, switch between conductive (open) and non-conductive (closed) states through a process called gating. + Two pore domain (K2P) potassium channels, originally called K background or leak channels, represent a subclass of K+ channels that function to establish and maintain the resting potential in eukaryotic cells. This process primes cells for diverse responses such as action potentials in excitatory cells and cell signaling cascades, which can direct growth and motility in non-excitable cell types. K2P channels have been shown to be gated by a range of cell stimuli and pharmacological agents including temperature, pH, polyunsaturated fatty acids, mechanical stress, and anesthetics. Not surprisingly, it is proposed that they are involved in physiological processes such as pain perception and anesthetic modulation. Structural studies of K2P channels would not only provide insight into how K2P channels are gated by these stimuli, but also may suggest strategies for the generation of K2P specific drugs.